Lindgren I, Bååth M, Uvebrant K, Dejmek A, Kjaer L, Henic E, Bungum M, Bungum L, Cilio C, Leijonhufvud I, Skouby S, Andersen C Yding, Giwercman Y Lundberg
Department of Translational Medicine, Molecular Genetic Reproductive Medicine, Clinical Research Centre, Lund University, Jan Waldenströms gata 35, Building 91, Plan 10, SE 20502 Malmö, Sweden
Department of Translational Medicine, Molecular Genetic Reproductive Medicine, Clinical Research Centre, Lund University, Jan Waldenströms gata 35, Building 91, Plan 10, SE 20502 Malmö, Sweden.
Hum Reprod. 2016 Mar;31(3):672-83. doi: 10.1093/humrep/dev342. Epub 2016 Jan 14.
Can gonadotrophin receptor variants separately or in combination, be used for the prediction of pregnancy chances in in vitro fertilization (IVF) trials?
The luteinizing hormone/human chorionic gonadotrophin receptor (LHCGR) variant N312S and the follicle-stimulating hormone receptor (FSHR) variant N680S can be utilized for the prediction of pregnancy chances in women undergoing IVF.
The FSHR N680S polymorphism has been shown to affect the ovarian response in response to gonadotrophin treatment, while no information is currently available regarding variants of the LHCGR in this context.
STUDY DESIGN, SIZE, DURATION: Cross-sectional study, duration from September 2010 to February 2015. Women undergoing IVF were consecutively enrolled and genetic variants compared between those who became pregnant and those who did not. The study was subsequently replicated in an independent sample. Granulosa cells from a subset of women were investigated regarding functionality of the genetic variants.
PARTICIPANTS/MATERIALS, SETTING, METHODS: Women undergoing IVF (n = 384) were enrolled in the study and genotyped. Clinical variables were retrieved from medical records. For replication, an additional group of n = 233 women was utilized. Granulosa cells from n = 135 women were isolated by flow cytometry, stimulated with Follitropin alpha or Menotropin, and the downstream targets 3',5'-cyclic adenosine monophosphate (cAMP) and inositol 1,4,5-trisphosphate (IP3) measured with enzyme-linked immunosorbent assay.
Women homozygous for serine (S) in both polymorphisms displayed higher pregnancy rates than women homozygous asparagine (N) (OR = 14.4, 95% CI: [1.65, 126], P = 0.016). Higher pregnancy rates were also evident for women carrying LHCGR S312, regardless of FSHR variant (OR = 1.61, 95% CI: [1.13, 2.29], P = 0.008). These women required higher doses of FSH for follicle recruitment than women homozygous N (161 versus 148 IU, P = 0.030). When combining the study cohort with the replication cohort (n = 606), even stronger associations with pregnancy rates were noted for the combined genotypes (OR = 11.5, 95% CI: [1.86, 71.0], P = 0.009) and for women carrying LHCGR S312 (OR = 1.49, 95% CI: [1.14, 1.96], P = 0.004). A linear significant trend with pregnancy rate and increasing number of G alleles was also evident in the merged study population (OR = 1.34, 95% CI: [1.10, 1.64], P = 0.004). A lower cAMP response in granulosa cells was noted following Follitropin alpha stimulation for women homozygous N in both polymorphisms, compared with women with other genotypes (0.901 pmol cAMP/mg total protein versus 2.19 pmol cAMP/mg total protein, P = 0.035).
LIMITATIONS, REASONS FOR CAUTION: Due to racial differences in LHCGR genotype distribution, these results may not be applicable for all populations.
Despite that >250 000 cycles of gonadotrophin stimulations are performed annually worldwide prior to IVF, it has not been possible to predict neither the pregnancy outcome, nor the response to the hormone with accuracy. If LHCGR and FSHR variants are recognized as biomarkers for chance of pregnancy, more individualized and thereby more efficient treatment modalities can be developed.
STUDY FUNDING, COMPETING INTERESTS: This work was supported by Interreg IV A, EU (grant 167158) and ALF governments grant (F2014/354). Merck-Serono (Darmstadt, Germany) supported the enrollment of the subjects. The authors declare no conflict of interest.
促性腺激素受体变异单独或联合使用时,能否用于预测体外受精(IVF)试验中的妊娠几率?
促黄体生成素/人绒毛膜促性腺激素受体(LHCGR)变异N312S和促卵泡激素受体(FSHR)变异N680S可用于预测接受IVF治疗女性的妊娠几率。
FSHR N680S多态性已被证明会影响对促性腺激素治疗的卵巢反应,而目前在这种情况下关于LHCGR变异尚无相关信息。
研究设计、规模、持续时间:横断面研究,从2010年9月至2015年2月。连续纳入接受IVF治疗的女性,并比较妊娠者与未妊娠者的基因变异情况。该研究随后在一个独立样本中进行重复。对一部分女性的颗粒细胞进行研究以探讨基因变异的功能。
参与者/材料、环境、方法:纳入接受IVF治疗的女性(n = 384)进行基因分型。从病历中获取临床变量。为进行重复研究,使用了另一组n = 233名女性。通过流式细胞术从n = 135名女性中分离颗粒细胞,用重组促卵泡素α或尿促性素刺激,并用酶联免疫吸附测定法测量下游靶点3',5'-环磷酸腺苷(cAMP)和肌醇1,4,5-三磷酸(IP3)。
两种多态性均为丝氨酸(S)纯合子的女性比天冬酰胺(N)纯合子女性显示出更高的妊娠率(OR = 14.4,95%CI:[1.65,126],P = 0.016)。携带LHCGR S312的女性,无论FSHR变异情况如何,也有更高的妊娠率(OR = 1.61,95%CI:[1.13,2.29],P = 0.008)。与N纯合子女性相比,这些女性募集卵泡需要更高剂量的FSH(161 IU对148 IU,P = 0.030)。当将研究队列与重复队列合并(n = 606)时,联合基因型(OR = 11.5,95%CI:[1.86,71.0],P = 0.009)以及携带LHCGR S312的女性(OR = 1.49,95%CI:[1.14,1.96],P = 0.004)与妊娠率的关联更强。在合并的研究人群中,妊娠率与G等位基因数量增加之间也存在明显的线性趋势(OR = 1.34,95%CI:[1.10,1.64],P = 0.004)。两种多态性均为N纯合子的女性,在重组促卵泡素α刺激后,颗粒细胞中的cAMP反应低于其他基因型女性(0.901 pmol cAMP/mg总蛋白对2.19 pmol cAMP/mg总蛋白,P = 0.035)。
局限性、谨慎理由:由于LHCGR基因型分布存在种族差异,这些结果可能不适用于所有人群。
尽管全球每年在IVF前进行超过250000周期的促性腺激素刺激,但此前无法准确预测妊娠结局或对激素的反应。如果LHCGR和FSHR变异被视为妊娠几率的生物标志物,那么可以开发出更个性化从而更有效的治疗方式。
研究资金、利益冲突:本研究得到欧盟区域间合作项目IV A(资助号167158)和ALF政府资助(F2014/354)支持。默克雪兰诺公司(德国达姆施塔特)支持了受试者的招募。作者声明无利益冲突。